Mark A Rosenthal
Overview
Explore the profile of Mark A Rosenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sim H, Wachsmuth L, Barnes E, Yip S, Koh E, Hall M, et al.
Neurooncol Adv
. 2023 Oct;
5(1):vdad124.
PMID: 37841696
Background: There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior trials. The NUTMEG study evaluated the combination of nivolumab and...
2.
Basiri Z, Yang Y, Bruinsma F, Nowak A, McDonald K, Drummond K, et al.
Cancer Causes Control
. 2022 Feb;
33(5):749-757.
PMID: 35184245
Purpose: High-grade disease accounts for ~ 70% of all glioma, and has a high mortality rate. Few modifiable exposures are known to be related to glioma risk or mortality. Methods:...
3.
Ellis J, Malalasekera V, Allan C, Choong P, Hansford J, Hehir R, et al.
J Adolesc Young Adult Oncol
. 2021 Jul;
11(2):173-180.
PMID: 34297611
International data demonstrate association between clinical trial participation and reduced cancer mortality. Adolescents and young adults (AYA) have low clinical trial enrollment rates. We established a program to understand local...
4.
Mweempwa A, Rosenthal M, Dimou J, Drummond K, Whittle J
J Clin Neurosci
. 2021 Jun;
89:144-150.
PMID: 34119258
Gliomas are a heterogeneous group of primary brain cancers with poor survival despite multimodality therapy that includes surgery, radiation and chemotherapy. Numerous clinical trials have investigated systemic therapies in glioma,...
5.
Olafson L, Siddell A, Field K, Byrnes M, Rapkins R, Ng B, et al.
J Clin Neurosci
. 2019 Oct;
70:157-163.
PMID: 31582283
The CABARET trial (ACTRN12610000915055) reported no difference in overall survival (OS) between patients with recurrent glioblastoma (GBM) randomized to either bevacizumab monotherapy or bevacizumab plus carboplatin. However, a subset of...
6.
Holmes A, Adams S, Hall S, Rosenthal M, Drummond K
Neurooncol Pract
. 2019 Aug;
2(2):88-92.
PMID: 31386066
Background: Tumors of the central nervous system (CNS) have physical and psychological effects that commonly interact and change over time. Although well suited to addressing problems at the interface between...
7.
Hovey E, Field K, Rosenthal M, Barnes E, Cher L, Nowak A, et al.
Neurooncol Pract
. 2019 Aug;
4(3):171-181.
PMID: 31386014
Background: In patients with recurrent glioblastoma, the benefit of bevacizumab beyond progression remains uncertain. We prospectively evaluated continuing or ceasing bevacizumab in patients who progressed while on bevacizumab. Methods: CABARET,...
8.
Lok S, Whittle J, Vaillant F, Teh C, Lo L, Policheni A, et al.
Cancer Discov
. 2018 Dec;
9(3):354-369.
PMID: 30518523
Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design,...
9.
Muscat A, Wong N, Drummond K, Algar E, Khasraw M, Verhaak R, et al.
Oncotarget
. 2018 Mar;
9(8):7844-7858.
PMID: 29487696
Glioblastoma presents as a heterogeneous disease with poor prognosis despite the use of multimodal therapy. Analysis of genomic DNA changes between initial diagnosis and recurrence in response to standard treatment...
10.
Field K, Fitt G, Rosenthal M, Simes J, Nowak A, Barnes E, et al.
Asia Pac J Clin Oncol
. 2017 Nov;
14(5):e359-e365.
PMID: 29114999
Aim: Assessment of magnetic resonance imaging (MRI) in glioblastoma can be challenging. For patients with recurrent glioblastoma managed on the CABARET trial, we compared disease status assessed at hospitals and...